Dual-Lineage IDLV–CRISPR/Cas9 Editing of MSCs and HSPCs Enhances GALNS-Mediated Cross-Correction in MPS IVA In Vitro
5 affiliations
- 1Department of Research, Nemours Children’s Hospital, 1600 Rockland Road, Wilmington, DE 19803, USA
- 2Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
- 3PuREC Co., Ltd., Izumo 693-8501, Japan
- 4Department of Life Science, Shimane University, Izumo 693-8501, Japan
- 5Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA
Abstract
Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), in which current therapies incompletely correct skeletal disease because enzyme delivery to avascular cartilage is limited. We developed a dual-lineage ex vivo gene-editing strategy combining murine hematopoietic stem/progenitor cells (mHSPCAAVS1) and rapidly expanding clonal human mesenchymal stem cells (REC-MSCs), using an integrase-defective lentiviral (IDLV) CRISPR/Cas9 platform designed to deliver a GALNS cassette to the AAVS1 safe-harbor locus. Nocodazole-mediated G2/M synchronization further increased GALNS output in HDR-competent conditions. Edited REC-MSCs showed supraphysiological GALNS production and secretion, and edited mHSPCAAVS1 reached approximately 13.9-fold wild-type activity; enhanced expression persisted at 30 days post-transduction. In non-contact transwell co-culture, edited REC-MSCs and edited mHSPCAAVS1 each increased GALNS activity in MPS IVA patient fibroblasts, and combined exposure produced the greatest correction, reducing lysosomal mass by ~36%, mono-sulfated keratan sulfate by ~54%, and mitochondrial superoxide toward wild-type levels at 30 days. Irradiated REC-MSC feeder layers supported 2.59-fold mHSPCAAVS1 expansion and a 1.96-fold higher proportion of EGFP-positive cells. Cross-correction was therefore achieved by each lineage and was greatest in combination, establishing a functional basis for in vivo evaluation of this dual-lineage strategy in MPS IVA.
Related
- BASELINE: a CRISPR base editing platform for mammalian-scale single-cell lineage tracing
- Comparison of Prime Editing and CRISPR-Cas Mediated HDR in Correcting CFTR-F508del Mutation in Patient iPSC-Derived Airway Basal Cells
- Protocol for eVLP-mediated CRISPR-Cas9 and prime editing in pancreatic cancer cell lines
- CRISPR/Cas9‐Mediated Correction of the SLC25A38 Mutation in a Patient With Sideroblastic Anemia
- LNP-mediated CRISPR gene editing of human vascular endothelial cells in 2D and 3D microfluidic cell culture systems
BibTeX
@article{nidhi2026duallineage,
title = {{Dual-Lineage IDLV–CRISPR/Cas9 Editing of MSCs and HSPCs Enhances GALNS-Mediated Cross-Correction in MPS IVA In Vitro}},
author = {Fnu Nidhi and Shaukat Khan and Takashi Suyama and Yumi Matsuzaki and Shunji Tomatsu},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210245},
url = {https://www.mdpi.com/1422-0067/27/22/10245},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dual-Lineage IDLV–CRISPR/Cas9 Editing of MSCs and HSPCs Enhances GALNS-Mediated Cross-Correction in MPS IVA In Vitro
AU - Fnu Nidhi
AU - Shaukat Khan
AU - Takashi Suyama
AU - Yumi Matsuzaki
AU - Shunji Tomatsu
PY - 2026
DA - 2026/11/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210245
UR - https://www.mdpi.com/1422-0067/27/22/10245
AB - Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), in which current therapies incompletely correct skeletal disease because enzyme delivery to avascular cartilage is limited. We developed a dual-lineage ex vivo gene-editing strategy combining murine hematopoietic stem/progenitor cells (mHSPCAAVS1) and rapidly expanding clonal human mesenchymal stem cells (REC-MSCs), using an integrase-defective lentiviral (IDLV) CRISPR/Cas9 platform designed to deliver a GALNS cassette to the AAVS1 safe-harbor locus. Nocodazole-mediated G2/M synchronization further increased GALNS output in HDR-competent conditions. Edited REC-MSCs showed supraphysiological GALNS production and secretion, and edited mHSPCAAVS1 reached approximately 13.9-fold wild-type activity; enhanced expression persisted at 30 days post-transduction. In non-contact transwell co-culture, edited REC-MSCs and edited mHSPCAAVS1 each increased GALNS activity in MPS IVA patient fibroblasts, and combined exposure produced the greatest correction, reducing lysosomal mass by ~36%, mono-sulfated keratan sulfate by ~54%, and mitochondrial superoxide toward wild-type levels at 30 days. Irradiated REC-MSC feeder layers supported 2.59-fold mHSPCAAVS1 expansion and a 1.96-fold higher proportion of EGFP-positive cells. Cross-correction was therefore achieved by each lineage and was greatest in combination, establishing a functional basis for in vivo evaluation of this dual-lineage strategy in MPS IVA.
SN - 1422-0067
ER -